ArticleEuropean journal of cancer (Oxford, England : 1990)2017

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.

Christophe Massard et al.PubMed ↗Publisher ↗

No numbers read from the abstract.